the effect of curcumin supplementation on depression, anxiety, pain and BDNF serum concentration in patients with gastrointestinal cancer

Phase 3

Recruiting

• Conditions: Gastrointestinal Malignancy.; Malignant neoplasm of ill-defined sites within the digestive system; C26.9

• Registration Number: IRCT20240521061860N1
• Lead Sponsor: Zahedan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 22 July 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 64

Inclusion Criteria

Men over 18 years old with gastrointestinal cancers
At least 6 months have passed since the onset of the disease.
They must meet the depression criteria according to DSM-5 criteria
They must be willing to participate in the study.
do not have any contraindications for prescribing curcumin.
No previous use of pharmaceutical antidepressants, no use of cigarettes and curcumin supplements.

Exclusion Criteria

People who are in the end stage of cancer.
Do not want to participate in the study.
Do not have depression criteria.
Patients under 18 years old
Patients with panic disorder, bipolar disorder, co morbid obsessive-compulsive disorder, post traumatic stress disorder, eating disorder, or any substance abuse or dependence disorder and people at high risk of suicide.
Patients with medical diseases such as diabetes, autoimmune diseases, cardiovascular diseases, high blood pressure, Alzheimer's disease, Parkinson's disease, stroke and multiple sclerosis, chronic fatigue syndrome, fibromyalgia and asthma.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression. Timepoint: Before starting the intervention, after completing the treatment period. Method of measurement: Beck depression questionnaire.;Anxiety. Timepoint: Before starting the intervention, after completing the treatment period. Method of measurement: Beck's anxiety questionnaire.;Pain. Timepoint: Before starting the intervention, after completing the treatment period. Method of measurement: Pain Self-Efficacy Questionnaire.;BDNF. Timepoint: Before starting the intervention, after completing the treatment period. Method of measurement: ELISA method.